Executive search services paired with “soup-to-nuts” discovery to commercial SAB experts to design & execute therapeutic asset and platform strategies, and resourcing solutions for early-stage biotech clients.

Advisory + Business role in Development and Market positioning Terpedia (in Stealth): the first personalized 'omics + AI in silico platform to drug the “Terpenome” (and the first >100k Terpene database); working directly with proteomics, genomics and AI/ML experts.

Advising Biotechs, Venture Capitals and Start-ups to help vet or recommend funding, commercial, partnering and drug discovery strategies for new technologies, potential assets or pipeline repositioning strategies. We deploy our deep scientific expertise and business experiences in Pharma, Biotech, Start-ups and a Consulting firm, with a large network of experts across chemistry & biology, pharma/biotech business, finance and leadership coaching. Also through fractional SAB, CSO or CEO contracts: advising start-ups (business model development, scientific and partnership strategies, people/talent strategies and market research) in a range of therapeutic or biomedical unmet needs, including: stewardship of molecules from discovery to development, platforms enabling AI in Drug Discovery or AI in personalized medicine, chemistry and cellular platforms, quantitative pharmacology, ‘omics data analysis, tissue engineering, biologics and natural products.

A 7 month contract to help pivot the company to a broader AI platform and an asset pipeline company. 1859 uses robust AI/ML models and in-silico approaches iteratively with vast high quality empirical data – 1859's design, make, and test cycles at the speed, volume of quality compounds and validation precision needed to realize the potential of AI for drug discovery. Helped connect AI/ML technologists with empirical chemists and biologists to align their very different perspectives and goals towards company and pipeline aspirations.Mentoring and advising on issues with company cultural and directional changes needed.

Responsibilities include driving new and more relevant ways to keep the Alliance on its mission to “Collaborate to Innovate”. A not-for-profit organization with over 200 member companies including 18 of the top 20 global pharma companies and across the life science ecosystem. In addition to serving as ambassador to grow membership and attendance, member of the project sub team overseeing more than 25 projects and communities to advance science with 20 Industry and vendor companies. Leader in establishing the Alliance into new, more relevant collaboration areas enabling AI in drug discovery. Organizer of the April 2023 conference Keynote Panel Discussions with >7 major Biopharma on “The use of AI, ‘omics and real-world data in pre-clinical research and early development.”

Established a new 50+ people global Research practice for Accenture Life Sciences. Built & sold digital strategies & offerings to help research organizations in Pharma and government labs accelerate research through more relevant, accessible data, modern digital tools, AI-powered dashboards & analytics, and in silico research practices:• Role as go-to-market lead and subject matter expert to develop an AI- driven personalized medicine “App” using data (RWD) from 50 million patients that is still yielding novel drug repurposing options and new clinical trial cohort selections.• Leader of a market survey of 20+ Pharma on the use of RWD/’omics with AI in Discovery. • Substantial involvement in Accenture’s Ventures team due diligences for start-ups and emerging Biotech as potential funding or acquisition targets, as related to core strategic growth areas (eg. AI) in Drug Discovery and early development. • Leading go-to-market strategies and partnership activities with funded or acquired companies.

1859: The New Origin of Medicines. A start-up seeded from an academic partnership I spearheaded while at Roche. Our iterative, DNA-encoded high-throughput drug discovery platform screens large small molecule diversity in disease relevant functional activity assays, one-thousand times cheaper and faster than conventional small molecule screening processes.

Consultation with start-ups, pharmaceutical and biotechnology companies and research organizations big and small, to move them to new levels of innovation and delivery. Tapping my enzymology expertise and large, diverse network of experts across biology & chemistry, we work on single project or contract-based consultations that are tailored to the organization, in the areas of: • Formulating start-ups’ Value Propositions and pitches for investment.• Designing & optimizing discovery strategies from target idea through clinical submission.• Defining optimal technologies, platforms and science needed to drive to success.• Advising on the people, culture & processes that can maximize performance: eg. optimal organizational set-ups & governance models, leadership styles, core competencies, living "diversity & inclusion", alignment/leveraging of global teams.

Leader of a global team with main accountabilities to modernize and streamline discovery research technologies, governance and people practices; working with search and evaluation teams to identify and fund >10 new strategic alliances & partnerships.➔ Boosted productivity ~10 fold by creation of a new translational discovery strategy, solving a ~20 FTE gap through externalization and procurement of $25M cutting edge infrastructure investments.➔ Promoted innovation and better employee engagement through connecting disparate, undervalued teams, resulting in new technologies (like antibody “floppiness” movies) and the first global D&I initiative for R&D.

Leader of a Discovery team with accountabilities for discovering 10-15 clinical candidate molecules per year in ~ 12 therapeutic areas. Built a reputation as an “agent for innovation” with skills in portfolio & platform development. ➔ Championed new therapeutic discovery strategies harnessing 2 large academic collaborations that enabled first-in-class designations like novel anti-bacterials and >12 enzyme-mechanism based therapeutics/INDs filed to the FDA.➔ Integrated science & people across the siloed units of R&D, manufacturing and vaccines to deliver platform innovations like a “bugs-to-drugs” green manufacturing initiative (GSK CEO endorsement) and novel vaccines.2000 – 2010: Additional Roles Held: Investigator, Group Leader, Discovery Program Leader, External Partnerships Liaison